The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | MURANO trial: duvelisib plus venetoclax in R/R CLL, SLL and Richter’s Syndrome
Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the updated results from the MURANO trial (NCT03534323): a Phase I/II study aiming to evaluate the efficacy and safety of combined fixed-duration duvelisib and venetoclax treatment in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) or Richter’s syndrome. This line of therapy was found to be generally well tolerated, with no dose-limiting toxicities or cases of tumor lysis syndrome being reported. Around 60% of the participants achieved a complete response and were able to discontinue treatment. These finding suggest that duvelisib and venetoclax may become a key approach in heavily pretreated populations. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
